The contributing effect of such changes on sleep problems in patients with type-2 diabetes may also be interesting to explore in future studies, as SGLT-2 inhibitors have yielded promising results for the treatment of OSA (Tanriover et al., 2023), and we cannot rule out that effect. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.